Join the Frontline for New Treatments
December 1st, 2015

If treatment options for desperately ill patients is your cause, then today is your day to help!  It's not too late to take part in #GivingTuesday!  

ALS Emergency Treatment Fund is the world's premier organization for Expanded Access to investigational medicine in life threatening diseases.    And we've been busy.  Read on for the big news from October and November.

Make a contribution today!


ALS-ETF featured in BioCentury

The November issue of BioCentury highlights the model for collaboratively sponsored Expanded Access programs, featuring the leader in the field,        ALS Emergency Treatment Fund.

Read Article Here!

New Options for Patients

ALS-ETF has developed several opportunities for partnership with drug companies whose products have made progress through clinical trials in ALS and other serious diseases.  Right now, we're working hard to finish deals with two particular companies so that we can run U.S. Expanded Access programs for them, hopefully to launch in the first half of 2016.   If anyone tells you it can't be done, send them to us.

Expanded Access Explainer!

ALS-ETF's Jess Rabourn at IDIS Workshop

On November 5th, ALS-ETF executive director Jess Rabourn spoke at the  "Insights for Access" conference, hosted by IDIS in Philadelphia

Watch the Video Here!

NYU / New York Academy of Sciences Symposium

On October 28-29, ALS-ETF participated in the groundbreaking event, "Pre-Approval Access:  Can Compassion, Business, and Medicine Co-Exist?"
Watch for their recap and newsletter, with reference to ALS-ETF's leadership in this space.


Expanded Access Webinar by ALS-ETF & ALS Association

On October 5th, ALS-ETF executive director Jess Rabourn delivered a one-hour webinar on the regulation and best practice of Expanded Access.  The event was co-hosted by ALS-ETF and ALS Association


Watch the Webex Replay Here!

ALS Emergency Treatment Fund (ALS-ETF) | San Jose, CA. | (415)-637-4774